FIELD: ophthalmology.
SUBSTANCE: invention relates to the use of an ophthalmic pharmaceutical composition comprising L-alanyl-L-glutamine, suspended or dissolved in an isosmotic solution, which is suitable for local administration to the eyes to increase goblet cell density, improve the function of the corneal epithelial barrier, eliminate corneal damage, achieve improvement in the symptoms of dry eye disease (DED) in a patient requiring such treatment.
EFFECT: above invention allows to use an ophthalmic pharmaceutical drug composition for the treatment of ASH with good efficacy, provides long-term use and has neither noticeable local nor local side effects.
13 cl, 3 dwg, 3 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CELECOXIB PRODRUG, METHOD FOR ITS PREPARATION AND USE | 2021 |
|
RU2822483C1 |
| Pharmaceutical composition based on tramadol for ophthalmic use | 2016 |
|
RU2744570C2 |
| POLYGLUTAMATE-AMINO ACID CONJUGATES AND METHODS | 2006 |
|
RU2472812C2 |
| METHOD FOR OBTAINING MODIFIED HYALURONIC ACID AND ITS SALTS | 2021 |
|
RU2804641C2 |
| PHARMACEUTICAL COMPOSITION BASED ON TRIINDOLYLMETHANE DERIVATIVE AS ANTI-TUMOUR MEDICATION | 2012 |
|
RU2549430C2 |
| EYE DROPS IN FORM OF SOLUTION CONTAINING BENZOPYRAN DERIVATIVE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT | 2019 |
|
RU2778515C2 |
| PREPARATIVE FORM OF ARGATROBAN | 2006 |
|
RU2416393C2 |
| DRUG FOR INJECTION BASED ON SAPONIN B4 PULSATILLA | 2017 |
|
RU2759382C2 |
| ASSOCIATES OF THE DEPROTONIZED HYALURONIC ACID, A METHOD OF THEIR PREPARING, PHARMACEUTICAL COMPOSITION CONTAINING ASSOCIATES OF THE DEPROTONIZED HYALURONIC ACID AND A METHOD OF ITS PREPARING | 1990 |
|
RU2099350C1 |
| PHARMACEUTICAL COMPOSITION FOR TOPICAL USE FOR TREATMENT OF EYE AND NOSE ALLERGIC DISEASES | 1993 |
|
RU2130774C1 |
